Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

OptiBiotix Health Plc

Company price
5.65 GBX 0.00(0%)
Last update at 2026-10-27T16:09:00Z
VOLUME
64672
Market Cap
5.42M

Momentum Score

…

OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulation products in the United Kingdom, the United States, India, China, and internationally. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology and derive potential health benefits. Its products include Slimbiome, which offers a scientifically supported, non-pharmaceutical approach to reduce hunger and cravings; CholBiome, a food supplement for reducing cholesterol and blood pressure and supporting vascular health; and Sweetbiotix which are dietary fibres used as an alternative to sugar and existing sweeteners. The company also provides WellBiome a novel in vitro model of the human gut; OptiBiotics, a portfolio of prebiotics developed to target and enhance the growth of specific probiotics; and SlimBiome X3, a supplement that helps users cut calories without hunger and cravings. The company was formerly known as Ducat Ventures PLC and changed its name to OptiBiotix Health Plc in August 2014. OptiBiotix Health Plc was incorporated in 2006 and is headquartered in York, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
5.50
Low
5.80
High
52 Week Price Range
4.66
Low
21.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
5.65
Dividend Yield
-
Revenue TTM
1.15M
Revenue Per Share
0.01
Gross Profit TTM
0.52M
Debt / Equity
0.05
ROE
-2.42%
Net Debt
-0.74M
ROCE
-26.12%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -1.87M -2.04M 2.44M 6.18M 5.71M
Minority interest - - 0.00M 0.00M 0.04M
Net income -1.80M -2.04M 2.59M 6.26M 5.80M
Selling general administrative 1.65M 1.70M 0.83M 0.93M 0.74M
Selling and marketing expenses 0.65M 0.12M 0.16M 0.11M 0.17M
Gross profit 0.33M 0.32M 0.24M 1.12M 0.88M
Reconciled depreciation 0.21M 0.20M 0.22M 0.29M 0.25M
Ebit -2.27M -2.04M -2.49M -1.37M -1.11M
Ebitda -2.06M -1.84M -2.35M -1.08M -1.17M
Depreciation and amortization 0.21M 0.20M 0.14M 0.29M -0.06M
Operating income -2.27M -1.70M -2.49M -1.37M -1.11M
Other operating expenses 3.14M 2.34M 2.94M 3.58M 2.63M
Interest expense - 0.00M 5.01M 0.05M 0.04M
Tax provision -0.06M -0.00M -0.15M -0.08M -0.09M
Interest income 0.00M 0.00M 0.00M 0.00M 0.00M
Net interest income 0.00M 0.00M 0.00M -0.05M -0.04M
Income tax expense -0.06M -0.00M -0.15M -0.08M -0.09M
Total revenue 0.87M 0.64M 0.46M 2.21M 1.52M
Total operating expenses 2.60M 2.02M 2.73M 2.49M 1.99M
Cost of revenue 0.54M 0.32M 0.21M 1.09M 0.64M
Total other income expense net 0.40M -0.35M 4.93M 7.54M 6.82M
Net income from continuing ops -1.80M -2.04M 2.59M 6.26M 5.80M
Net income applicable to common shares - - 2.59M 6.26M 5.80M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 9.04M 9.40M 11.55M 20.14M 13.70M
Intangible assets 1.12M 1.33M 1.54M 2.64M 2.74M
Other current assets 0.02M 0.10M - 1.74M 0.96M
Total liab 0.65M 0.53M 0.64M 1.97M 1.85M
Total stockholder equity 8.40M 8.87M 10.90M 18.14M 11.82M
Other current liab 0.10M 0.12M 0.09M 0.18M 0.16M
Common stock 1.96M 1.82M 1.82M 1.76M 1.76M
Capital stock 1.96M 1.82M 1.82M 1.76M 1.76M
Retained earnings 0.58M 1.82M 3.68M 11.32M 5.06M
Other liab - - 0.36M 0.55M 0.56M
Cash 0.74M 0.64M 1.05M 2.01M 0.86M
Total current liabilities 0.37M 0.18M 0.28M 0.60M 0.52M
Net debt -0.74M -0.64M -1.05M -1.19M -0.09M
Short long term debt total - - - 0.82M 0.77M
Other stockholder equity 4.11M 2.96M 5.40M 5.06M 5.00M
Total current assets 1.42M 1.38M 1.86M 3.85M 2.01M
Net tangible assets - - 9.37M 15.50M 9.08M
Net receivables 0.43M 0.46M 0.38M 1.69M 0.93M
Long term debt - - 0.00M 0.82M 0.77M
Inventory 0.23M 0.19M 0.18M 0.10M 0.18M
Accounts payable 0.27M 0.06M 0.19M 0.42M 0.36M
Accumulated other comprehensive income 1.75M 2.27M - - -0.01M
Common stock total equity - - - - 1.76M
Non currrent assets other - - 8.15M 13.65M 8.96M
Non current assets total 7.62M 8.02M 9.69M 16.29M 11.70M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments 0.59M 1.11M -0.33M -0.19M -0.35M
Change to liabilities - - -0.02M 0.08M -0.04M
Total cashflows from investing activities 0.59M 1.11M -0.33M -0.19M -0.35M
Total cash from financing activities 1.28M - 0.48M 2.90M 1.69M
Net income -2.27M -2.04M -2.49M -1.37M -1.11M
Change in cash 0.10M -0.42M -0.95M 1.14M 0.41M
Begin period cash flow 0.64M 1.05M 2.01M 0.86M 0.46M
End period cash flow 0.74M 0.64M 1.05M 2.01M 0.86M
Total cash from operating activities -1.77M -1.53M -1.11M -1.56M -0.93M
Issuance of capital stock 1.28M 0.00M 0.48M 0.00M 0.94M
Depreciation 0.21M 0.20M 0.22M 0.29M 0.25M
Other cashflows from investing activities - 1.11M - - -
Change to inventory -0.04M -0.01M -0.08M 0.08M -0.12M
Change to account receivables 0.03M 0.06M 1.12M -0.91M -0.04M
Other cashflows from financing activities - 1.11M -0.33M 2.90M 0.75M
Change to netincome - - -4.94M -7.37M -6.78M
Capital expenditures 0.00M 0.00M 0.17M 0.19M 0.35M
Change in working capital 0.17M -0.05M 1.02M -0.74M -0.20M
Stock based compensation 0.05M 0.01M 0.01M 0.06M 0.13M
Other non cash items 0.07M 0.35M 0.12M 0.19M 0.01M
Free cash flow -1.77M -1.53M -1.28M -1.76M -1.28M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
OPTI
OptiBiotix Health Plc
-
-%
5.65 - - 4.71 0.64 3.54 -1.39
GNS
Genus PLC
18.00
0.78%
2340.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd
10.60
4.93%
225.60 - - 4.71 2.50 4.23 -8.89
OXB
Oxford BioMedica PLC
5.00
0.95%
532.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC
-1.00
1.60%
61.50 - - 2849.46 1929.84 2525.51 -12.04

Profile*

OptiBiotix Health Plc

OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulation products in the United Kingdom, the United States, India, China, and internationally. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology and derive potential health benefits. Its products include Slimbiome, which offers a scientifically supported, non-pharmaceutical approach to reduce hunger and cravings; CholBiome, a food supplement for reducing cholesterol and blood pressure and supporting vascular health; and Sweetbiotix which are dietary fibres used as an alternative to sugar and existing sweeteners. The company also provides WellBiome a novel in vitro model of the human gut; OptiBiotics, a portfolio of prebiotics developed to target and enhance the growth of specific probiotics; and SlimBiome X3, a supplement that helps users cut calories without hunger and cravings. The company was formerly known as Ducat Ventures PLC and changed its name to OptiBiotix Health Plc in August 2014. OptiBiotix Health Plc was incorporated in 2006 and is headquartered in York, the United Kingdom.

Innovation Centre, York, United Kingdom, YO10 5DG

10

Name Title Year Born
Mr. Stephen Patrick O'Hara Founder, CEO & Exec. Director NA
Dr. Sofia Kolyda Exec. Director of R&D and Exec. Director 1973
Mr. Rene Kamminga CEO of Functional Fibres & Director NA
Mr. Mark Kingsley Collingbourne CFO & Sec. 1966
Paul Cannings Head of Operations & Quality NA
Kevin James Newman Corp. Devel. Director NA
Mr. Karl Burkitt Marketing Director NA
Mr. Stephen Patrick O'Hara Founder, CEO & Executive Director 1960
Dr. Sofia Kolyda Executive Director of Research & Development and Executive Director 1973
Mr. David Jonathan Blain ACA CFO, Company Secretary & Director 1961

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…